Original from: bioM¨¦rieux

The Board of Directors of bioM¨¦rieux, a world leader in the field of in vitro diagnostics, met on September 3, under the chairmanship of Alexandre M¨¦rieux and approved the consolidated financial statements for the six months ended June 30, 2025.

¡¤ +9.4% organic sales growth in H1 25, reaching €2,044 million, driven by a +10% organic sales increase across the four growth drivers of the GO•28 strategic plan and +12% organic sales growth in BIOFIRE® respiratory panels:

 - BIOFIRE® non-respiratory panels: +10% organic growth, a solid performance evenly distributed across all regions;

 - SPOTFIRE®: continued expansion with €79 million in H1 25 sales, marking a +143% organic increase compared to last year;

 - Microbiology: +3% organic sales growth, impacted by a double digit decline in China;

 - Industrial Applications: +10% organic sales growth, supported by a strong mid-teens growth in the Pharma Quality Control segment;

 - BIOFIRE® respiratory panels: +12% organic sales growth, largely driven by the relevance of the solution amid very high epidemiological activity in Q1 25.

¡¤ €946 million of sales in Q2 2025, representing a +6.1% like-for-like increase and +8% organic sales growth excluding China

¡¤ Contributive operating income before non-recurring items (CEBIT) reached €372  million in H1 25, a remarkable +24% like-for-like evolution versus H1 24. The H1 25 CEBIT margin stands at 18.2% of sales, up +210bps compared to H1 24.

¡¤ Net income (group share) amounted to €161m, down 25% compared to H1 2024, impacted by the partial impairment of the Reveal technology.

¡¤ Excellent free cash-flow generation at €170 million in H1 25, up more than 3 times compared to H1 2024, driven by EBITDA increase and working capital management.

¡¤ Adjustment of the 2025 full year guidance: sales are now expected to grow organically by +6% to +7.5% (initially ¡°at least +7%¡±) impacted by China market decline and CEBIT is expected to grow by +12% to +18% organically (initially ¡°at least +10%¡±) driven by improved operating leverage. The 2025 full year currency effect is now expected to be negative in the range of -€25m (previously -€35m to -€40m).

Pierre Boulud, Chief Executive Officer, said: "With a strong increase in profitability in the first half of 2025, bioM¨¦rieux confirms the relevance of the GO28 plan in a complex economic and geopolitical environment. At the same time, we have continued to invest in preparing bioM¨¦rieux¡¯s future growth through the acquisition of SpinChip Diagnostics - a promising Point-of-Care immunoassays technology ¨C as well as the next-generation sequencing assets from Day Zero Diagnostics.¡±

Source: bioM¨¦rieux ¨C First-Half 2025 Results